---
layout: minimal-medicine
title: Gadobenate Dimeglumine
---

# Gadobenate Dimeglumine
### Generic Name
Gadobenate Dimeglumine

### Usage
Gadobenate dimeglumine is a gadolinium-based contrast agent used primarily in magnetic resonance imaging (MRI) scans. Its main purpose is to enhance the visibility of various structures and lesions within the body, improving the diagnostic accuracy of the MRI.  Specifically, it's used to visualize central nervous system (CNS) lesions with abnormal blood-brain barrier permeability or abnormal vascularity in the brain and spine. It's also employed to evaluate renal and aortoiliofemoral occlusive vascular disease.  The contrast agent helps highlight areas of interest, making it easier for radiologists to identify and characterize abnormalities.

### Dosage

Dosage varies depending on the type of scan and the patient's age and weight.  Always follow the instructions provided by your healthcare professional.

**CNS imaging (Adults and Children â‰¥2 years):**

* Intravenous (IV) administration: 0.1 mmol/kg (0.2 mL/kg) for adults and 0.2 mL/kg (0.1 mmol/kg) for children. Imaging can begin immediately after administration.

**CNS imaging (Children <2 years):**

* Intravenous (IV) administration: 0.1-0.2 mL/kg (0.05-0.1 mmol/kg). Imaging can begin immediately after administration.

**Renal and aorto-ilio-femoral vasculature imaging (Adults):**

* Intravenous (IV) administration: 0.1 mmol/kg (0.2 mL/kg). A test bolus (1-2 mL) may be used to determine the optimal scan delay, or automatic detection techniques may be employed.

**Dosage Adjustments:**  The manufacturer's labeling does not provide specific dosage adjustments for hepatic impairment.  For patients with renal impairment, no specific dosage adjustments are provided, but use should be approached with caution due to the increased risk of nephrogenic systemic fibrosis (NSF).  Hemodialysis may be considered promptly (within 3 hours) after administration in patients undergoing hemodialysis. Peritoneal dialysis is less efficient at clearing gadolinium.  More frequent cycles may be needed if hemodialysis isn't an option.


### Side Effects

**Common Side Effects (1-10%):**

* Feeling hot
* Headache
* Nausea
* Vomiting
* Injection site reaction

**Less Common but Serious Side Effects (<1%, postmarketing and/or case reports):**

* Anaphylactic shock/anaphylaxis
* Abdominal pain
* Altered sense of smell
* Chest pain
* Chills
* Diarrhea
* Dizziness
* Dyspnea (shortness of breath)
* ECG abnormalities
* Facial edema
* Fatigue
* Fever
* Hypersensitivity reactions
* Laryngospasm
* Loss of consciousness
* Pulmonary edema
* Seizure
* Shock
* Skin rash
* Swelling of lips/tongue
* Urticaria (hives)
* Wheezing


If you experience any adverse effects, consult your healthcare provider immediately.  The list above isn't exhaustive, and other side effects are possible.

### How it Works

Gadobenate dimeglumine is a paramagnetic contrast agent containing gadolinium.  When placed in a magnetic field (during an MRI), it alters the magnetic properties of the surrounding water molecules. This alteration in the magnetic resonance signal results in increased signal intensity in the areas where the contrast agent has accumulated.  This improved signal contrast allows for better visualization of blood vessels, lesions, and other anatomical structures during the MRI scan.  The agent's distribution within the body is largely determined by blood flow and the integrity of the blood-brain barrier.


### Precautions

* **Contraindicated:** In patients with a known hypersensitivity to gadobenate dimeglumine, other gadolinium-based contrast agents, or any component of the formulation.

* **Increased Risk:**  There's an increased risk of cardiac arrhythmias, extravasation (leakage from the vein), hypersensitivity reactions, and gadolinium retention.  Most importantly, patients with impaired renal function are at significantly increased risk of nephrogenic systemic fibrosis (NSF), a potentially fatal condition.

* **Use with Caution:** Exercise caution in patients with metabolic disorders or renal impairment.  Carefully interpret contrast-enhanced MR images, comparing them with non-contrast images when available.

* **Nephrogenic Systemic Fibrosis (NSF):**  This is a serious boxed warning.  Gadobenate dimeglumine, like other gadolinium-based contrast agents, carries a risk of NSF, especially in patients with severely impaired kidney function (GFR <30 mL/minute/1.73 m2).  Avoid use in these patients unless the information is essential and unavailable by other means.  Careful assessment of renal function is crucial before administration.


### FAQs

* **Q: How is Gadobenate Dimeglumine administered?**
    * **A:** It's administered intravenously (IV) as a rapid bolus injection.

* **Q: How long does it take to be eliminated from the body?**
    * **A:**  Elimination primarily occurs through the kidneys. The speed depends on renal function.

* **Q: What should I do if I experience a reaction?**
    * **A:** Immediately inform the medical personnel conducting the MRI.

* **Q: Can I drive after the MRI?**
    * **A:** Unless otherwise advised by your doctor, driving should not be affected. However, some side effects (like dizziness) could impact your ability to drive safely.

* **Q: How is Gadobenate Dimeglumine stored?**
    * **A:** Follow the specific storage instructions on the product labeling.  Generally, it should be stored at room temperature and protected from light.

* **Q: Are there any long-term effects?**
    * **A:**  The primary long-term concern is nephrogenic systemic fibrosis (NSF), but this is rare and primarily affects patients with severe kidney problems.

**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Always consult a healthcare professional for diagnosis, treatment, and any questions regarding your specific medical condition or before starting any new medication.
